As of November 6, 2026, Precision BioSciences, Inc. is a publicly traded company (Nasdaq: DTIL); its largest reported holder is Aberdeen Group plc, with 8.88% on Schedule 13G of January 27, 2026, then Bleichroeder LP (8.21%). The largest insider holding is Michael Amoroso, the chief executive and president, with 243,392 shares (0.87% of shares outstanding), per Form 4 of February 19, 2026 (Schedule 13G, January 27, 2026).
Is this your company?
About to sign with, pay or invest in Precision BioSciences, Inc.? See the free Snapshot first.
Free to see. No signup.
Is Precision BioSciences, Inc. a real, registered company?
- Precision BioSciences, Inc. files with the SEC under CIK 1357874 (its SEC filings).
- Its shares are listed under the ticker DTIL on Nasdaq (SEC company record).
- Incorporated in Delaware; business address in Durham, North Carolina, as its SEC filings state.
- Court and bankruptcy records: see Before you sign or pay below.
Before you sign or pay
- Court and bankruptcy: No federal court case or bankruptcy filing found under Precision BioSciences, Inc. in our court records and SEC 8-K records (as of 2026-11-06).
- Leadership changes: the latest reported is Alex Kelly, Chief Operating Officer (Form 8-K filed 2026-07-27). Check you are dealing with the people now in charge.
- Ownership: 5%+ holders are reported on Schedule 13D or 13G; the latest names Octagon Capital Advisors LP (filed 2026-11-03).
Who are Precision BioSciences, Inc.'s owners and officers?
Precision BioSciences, Inc.: incorporated in Delaware; business address in Durham, North Carolina; industry Biological Products, (No Diagnostic Substances) (Schedule 13G/A, 2026-11-03).
| Report | Holder | Share |
|---|---|---|
| Schedule 13G/A, 2026-11-03 | Octagon Capital Advisors LP | 5.73% |
| Schedule 13G, 2026-10-27 | Blackrock, Inc. | 5.01% |
| Schedule 13G/A, 2026-08-24 | Weinstein Benjamin | 4% |
| Schedule 13G/A, 2026-07-29 | Empery Asset Management, LP | 4.99% |
| Schedule 13G, 2026-07-20 | Lynx1 Capital Management LP | 5.4% |
| Schedule 13G/A, 2026-04-15 | Empery Asset Management, LP | 7.63% |
| Schedule 13G/A, 2026-02-17 | Lynx1 Capital Management LP | 4.1% |
| Schedule 13G/A, 2026-02-17 | Tang Capital Management, LLC | 0% |
| Schedule 13G/A, 2026-02-13 | Bleichroeder LP | 8.21% |
| Schedule 13G, 2026-02-10 | Octagon Capital Advisors LP | 9.99% |
| Schedule 13G, 2026-01-27 | Aberdeen Group PLC | 8.88% |
| Schedule 13G, 2026-01-22 | Empery Asset Management, LP | 9.99% |
Questions about who owns Precision BioSciences, Inc.
Who owns Precision BioSciences, Inc.?
On this page, 5 holders' latest ownership filings report 5% or more of Precision BioSciences, Inc.: Aberdeen Group PLC (8.88%, Schedule 13G, filed 2026-01-27), Bleichroeder LP (8.21%, Schedule 13G/A, filed 2026-02-13), Octagon Capital Advisors LP (5.73%, Schedule 13G/A, filed 2026-11-03), Lynx1 Capital Management LP (5.4%, Schedule 13G, filed 2026-07-20) and Blackrock, Inc. (5.01%, Schedule 13G, filed 2026-10-27).
Who are the largest shareholders of Precision BioSciences, Inc.?
By the share each holder's latest filing reports, the largest holders of Precision BioSciences, Inc. on this page are Aberdeen Group PLC (8.88%), Bleichroeder LP (8.21%) and Octagon Capital Advisors LP (5.73%).
When did Aberdeen Group PLC buy into Precision BioSciences, Inc.?
The filings give report dates, not purchase dates. The earliest filing from Aberdeen Group PLC on this page is the Schedule 13G, filed 2026-01-27, reporting 8.88%.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Want the whole picture on Precision BioSciences, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Precision BioSciences, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Precision BioSciences, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
19 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
| Filed | Person | Role | Change | Effective |
|---|---|---|---|---|
| Form 8-K, 2026-07-27 | Alex Kelly | Chief Operating Officer | appointed | |
| Form 8-K, 2026-07-27 | Naresh Tanna | Chief Financial Officer | appointed | |
| Form 8-K, 2026-07-27 | Mei Burris | Chief Accounting Officer | appointed |
Which insiders own Precision BioSciences, Inc. shares?
Directors, officers and holders of 10% or more report their shares on Forms 3, 4 and 5. Each line is the latest such report, largest holding first.
- , the chief executive and president: 243,392 shares (0.87% of shares outstanding) (Form 4, 2026-02-19).
- , the chief research officer: 129,857 shares (0.46% of shares outstanding), 121,926 held directly and 7,931 indirectly (Form 4, 2026-02-19).
- , the chief financial officer: 125,883 shares (0.45% of shares outstanding) (Form 4, 2026-02-19).
- , the general counsel and secretary: 56,457 shares (0.20% of shares outstanding) (Form 4, 2026-02-19).
- , a director: 49,137 shares (0.18% of shares outstanding) (Form 4, 2026-05-22).
Shares outstanding: 27,935,719 as of 2026-10-29, from the company's latest SEC cover page.
How much has Precision BioSciences, Inc. raised?
No fundraising or offering filing from Precision BioSciences, Inc. is on file with us.
Keep reading
More on Precision BioSciences, Inc. and the records around it.
Precision BioSciences, Inc. elsewhere on the record
- 5%+ stake filings Nov 2026
- Leadership changes Jul 2026
Companies that share a holder
- Readout Capital, LP also filed stake reports on 1 other company: TScan Therapeutics, Inc. (Sep 2026)
- Octagon Capital Advisors LP also filed stake reports on 8 other companies: Context Therapeutics Inc. (Jul 2026), Corbus Pharmaceuticals Holdings, Inc. (May 2026), Dianthus Therapeutics, Inc. /DE/ (May 2026)
- Lynx1 Capital Management LP also filed stake reports on 11 other companies: C4 Therapeutics, Inc. (Aug 2026), GH Research PLC (Aug 2026), iBio, Inc. (Aug 2026)
Related pages
Filings, cases and notices link to their records. A not-found line names the records searched; it is not proof of absence.
Not for employment, credit, insurance or tenancy decisions.
Cite this page
https://mentionfox.com/who-owns/precision-biosciences